The aforementioned findings corroborate another study in which a gradual increase in the JAK2 V617F allele burden was the most powerful predictor of PV/ET progression to secondary MF during cytoreductive therapy (hazard ratio 10.8) [71]. Here, JAK2 is linked to acquired polycythemia vera.